SP2509: Selective LSD1 Inhibitor for Acute Myeloid Leukemia Research

Executive Summary: SP2509 (SKU B4894) is a highly selective LSD1 inhibitor with an IC50 of 13 nM and does not affect MAO-A or MAO-B enzymatic activity (APExBIO). It disrupts the LSD1-CoREST complex, resulting in increased H3K4 trimethylation and upregulation of tumor suppressor genes such as p53, p21, and C/EBPα (SP2509 and the Next Frontier in AML Epigenetics). In human AML cell lines, SP2509 reduces colony formation, induces apoptosis, and promotes differentiation (Ali et al., 2021). In vivo, it significantly prolongs survival in NOD/SCID mice bearing AML xenografts at 25 mg/kg, twice weekly intraperitoneal dosing (APExBIO). SP2509 is insoluble in water/ethanol but is highly soluble in DMSO at ≥19.45 mg/mL and should be stored at -20°C for maximal stability (APExBIO).

Biological Rationale

Lysine-specific demethylase 1 (LSD1, also known as KDM1A) is an epigenetic regulator that catalyzes the demethylation of mono- and di-methylated lysine 4 on histone H3 (H3K4me1/2), modifications linked to transcriptional repression (Ali et al., 2021). Overexpression of LSD1 is documented in several cancers, including acute myeloid leukemia (AML), and correlates with poor prognosis. LSD1 forms complexes with CoREST and other chromatin factors, modulating gene expression by altering chromatin states. Inhibition of LSD1 reactivates tumor suppressor programs and can overcome differentiation blocks in AML. Targeting LSD1 is thus a rational strategy for modulating cancer epigenetics, particularly in myeloid malignancies. SP2509 was developed to address the need for potent, selective, and research-compatible LSD1 antagonists (APExBIO).

Mechanism of Action of SP2509

SP2509 binds to LSD1, inhibiting its demethylase activity with high potency (IC50 = 13 nM) and selectivity (no effect on MAO-A/MAO-B) (APExBIO). Importantly, SP2509 interferes with the LSD1-CoREST interaction, a key driver of chromatin-mediated transcriptional repression. This disruption increases H3K4 trimethylation (H3K4Me3) at target promoters, reactivating genes involved in cell cycle arrest and differentiation, including p53, p21, and C/EBPα. The resultant epigenetic reprogramming induces apoptosis and promotes terminal differentiation in AML cells. Unlike some non-selective demethylase inhibitors, SP2509 does not inhibit monoamine oxidases, minimizing off-target effects. These properties distinguish SP2509 as an advanced tool for dissecting the histone H3K4 demethylation pathway and evaluating the therapeutic potential of LSD1 inhibition in cancer research (SP2509: Next-Generation LSD1 Inhibitor—this article provides a broader mechanistic context, while the present article details workflow and selectivity parameters).

Evidence & Benchmarks

• SP2509 inhibits LSD1 enzymatic activity with an IC50 of 13 nM in biochemical assays at 25°C, pH 7.4 (APExBIO).
• SP2509 does not inhibit MAO-A or MAO-B at concentrations up to 10 μM, ensuring high selectivity (APExBIO product data: source).
• In OCI-AML3 and MOLM13 human AML cell lines, SP2509 induces apoptosis and differentiation, and reduces colony formation in soft agar assays (Ali et al., 2021, DOI:10.7150/ijbs.62236).
• Primary AML patient samples treated with SP2509 show increased H3K4Me3, upregulation of p53, p21, and C/EBPα, and enhanced differentiation markers (Ali et al., 2021, DOI:10.7150/ijbs.62236).
• In vivo, SP2509 (25 mg/kg, i.p., twice weekly) significantly improves survival in NOD/SCID mice bearing AML xenografts compared to vehicle controls (APExBIO; Ali et al., 2021, DOI:10.7150/ijbs.62236).
• SP2509 in combination with panobinostat, a pan-histone deacetylase inhibitor, yields synergistic survival benefit in AML xenograft models (Ali et al., 2021, DOI:10.7150/ijbs.62236).
• SP2509 is insoluble in water and ethanol but dissolves in DMSO at ≥19.45 mg/mL at 25°C (APExBIO product sheet: source).

Applications, Limits & Misconceptions

SP2509 is widely used in preclinical AML research to interrogate LSD1 function, model epigenetic reprogramming, and explore therapeutic combinations. Its selectivity enables precise studies of the histone H3K4 demethylation pathway and apoptosis induction in AML cells. SP2509 should not be used for in vivo diagnostic or medical applications, as it is intended for research use only.

• SP2509 (SKU B4894): Enhancing Reproducibility in AML Epigenetics—whereas that article focuses on troubleshooting and assay robustness, the present piece provides deeper context on selectivity, storage, and combinatorial strategy.
• SP2509 (SKU B4894): Reliable LSD1 Inhibitor for AML and Cancer Epigenetics—this guide is scenario-driven; here, we focus on mechanistic evidence and specific benchmarked outcomes.

Common Pitfalls or Misconceptions

• SP2509 is not effective in models where LSD1 is not a key dependency; efficacy is context-dependent and should be benchmarked against appropriate controls.
• The compound is not water- or ethanol-soluble; improper solvent use can confound assay results.
• It is not a pan-demethylase inhibitor and does not inhibit MAO-A or MAO-B, so is unsuitable for studies requiring broad-spectrum demethylase inhibition.
• SP2509 is for research use only; it is not validated for human or veterinary therapeutic use.
• Long-term storage of SP2509 solutions is not recommended; fresh solutions should be prepared for each experiment.

Workflow Integration & Parameters

SP2509 is supplied as a solid, with a molecular weight of 437.90 and chemical formula C19H20ClN3O5S (APExBIO). For dissolution, use DMSO at ≥19.45 mg/mL, optionally warming to 37°C or using an ultrasonic bath for improved solubility. The compound is insoluble in water and ethanol. Store powder at -20°C in a desiccated environment. Prepare working solutions immediately prior to use; avoid prolonged storage of diluted solutions. For in vivo studies, SP2509 has been administered intraperitoneally in NOD/SCID mice at 25 mg/kg, twice weekly, with documented survival benefit (Ali et al., 2021).

For cell-based assays, titrate concentrations to match published IC50 and benchmark apoptosis, differentiation, and colony formation endpoints in appropriate AML cell lines (e.g., OCI-AML3, MOLM13). For workflow compatibility and troubleshooting, see SP2509 (SKU B4894): Enhancing Reproducibility in AML Epigenetics.

APExBIO, the originating company, provides detailed product specifications and validated protocols for SP2509 (product page).

Conclusion & Outlook

SP2509 has become a gold-standard LSD1 inhibitor for acute myeloid leukemia research. By targeting the LSD1-CoREST complex and inducing specific epigenetic changes, it enables robust modeling of differentiation and apoptosis in AML systems. Its selectivity and reproducibility support its use in combination approaches (e.g., with panobinostat) to interrogate cancer epigenetics and therapy resistance. While designed for research use, SP2509 continues to inform the next generation of epigenetic modulators and translational strategies for AML and related malignancies. For advanced mechanistic insights and applications, see SP2509 and the Next Frontier in AML Epigenetics, which offers a broader translational context compared to the present workflow-oriented summary.